Literature DB >> 2545002

Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes.

S E Straus1, M Seidlin, H E Takiff, J F Rooney, J M Felser, H A Smith, P Roane, F Johnson, C Hallahan, J M Ostrove.   

Abstract

Twenty-six men and women with recurrent genital herpes maintained diaries of their symptoms and signs of infection and submitted 6,515 self-collected cultures during a one-year study of acyclovir therapy. As compared with periods before or after treatment, the mean rates of experiencing symptoms or lesions, and of shedding virus were significantly lower during treatment. Acyclovir treatment reduced the rate of symptomatic shedding from 95 positive cultures to six per 1,000 cultures, but the rate of asymptomatic shedding remained relatively constant, averaging eight per 1,000 cultures. Among the isolates of herpes simplex virus studied, there was no differences in sensitivity to acyclovir between strains recovered on or off therapy or during symptomatic or asymptomatic recurrences. The endonuclease cleavage profiles of asymptomatically shed viruses were essentially the same as those of the symptomatically shed viruses from the same individual. Chronic acyclovir therapy significantly reduced the symptoms and signs of recurrent genital herpes but did not eliminate virus shedding, nor, therefore, the possibility of disease transmission.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545002     DOI: 10.1097/00007435-198904000-00013

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  11 in total

1.  Recent developments in genital herpes.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1992-07

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Toward the rational management of herpes infection in pregnant women and their newborn infants. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-05-01       Impact factor: 8.262

4.  Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.

Authors:  M Lipsitch; T H Bacon; J J Leary; R Antia; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 5.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

6.  Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2.

Authors:  D N Fisman; E W Hook; S J Goldie
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

7.  From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections.

Authors:  Marcia M Hobbs; Barbara van der Pol; Patricia Totten; Charlotte A Gaydos; Anna Wald; Terri Warren; Rachel L Winer; Robert L Cook; Carolyn D Deal; M Elizabeth Rogers; Julius Schachter; King K Holmes; David H Martin
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830

Review 8.  Genital herpes: review of the epidemic and potential use of type-specific serology.

Authors:  R L Ashley; A Wald
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 9.  Genital herpes. A guide to pharmacological therapy.

Authors:  A de Ruiter; R N Thin
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 10.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.